The effects of pharmaceutical marketing and promotion on adverse drug events and regulation

American Economic Journal: Economic Policy

Volumn 2, Issue 4, 2010, Pages 1-25

  David, Guy ^a   Markowitz, Sara ^b   Richards Shubik, Seth ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b EMORY UNIVERSITY   (United States)

^c CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85017151885     PISSN: 19457731     EISSN: 1945774X     Source Type: Journal    
DOI: 10.1257/pol.2.4.1     Document Type: Article

References (37)

1. Almasi, Elizabeth A., Randall S. Stafford, Richard L. Kravitz, and Peter R. Mansfield. 2006. "What are the Public Health Effects of Direct-to-Consumer Drug Advertising?" PLoS Medicine, 3(3).
2. Ashraf, Nava, James Berry, and Jesse M. Shapiro. Forthcoming. "Can Higher Prices Stimulate Product Use? Evidence from a Field Experiment in Zambia." American Economic Review.
3. Baciu, Alina, Kathleen Stratton, and Sheila P. Burke, ed. 2007. The Future Of Drug Safety: Promoting And Protecting The Health Of The Public. Washington, DC: The National Academies Press.
4. Berndt, Ernst R. 2007. "The United States' Experience with Direct-to-Consumer Advertising of Prescription Drugs: What Have We Learned?" In Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, ed. Frank A. Sloan and Chee-Ruey Hsieh, 174-95. Cambridge, UK: Cambridge University Press.
5. Berndt, Ernst R., Adrian H. B. Gottschalk, Tomas J. Philipson, and Matthew W. Strobeck. 2005. "Industry Funding of the FDA: Effects of PDUFA on Approval Times and Withdrawal Rates." Nature Reviews Drug Discovery, 4(7): 545-54.
6. Bradford, W. David, Andrew N. Kleit, Paul J. Nietert, Terrence Steyer, Thomas McIlwain, and Steven Ornstein. 2006. "How Direct-To-Consumer Television Advertising For Osteoarthritis Drugs Affects Physicians' Prescribing Behavior." Health Affairs, 25(5): 1371-77.
7. Brekke, Kurt R., and Michael Kuhn. 2006. "Direct to Consumer Advertising in Pharmaceutical Markets." Journal of Health Economics, 25(1): 102-30.
8. Brick, Ivan E., and Harsharanjeet S. Jagpal. 1981. "Monopoly Price-Advertising Decision-Making under Uncertainty." Journal of Industrial Economics, 29(3): 279-85.
9. Buckley, Joan. 2004. "The Need to Develop Responsible Marketing Practice in the Pharmaceutical Sector." Problems and Perspectives in Management, 4: 92-103.
10. Cameron, A. Colin, and Pravin K. Trivedi. 1998. Regression Analysis of Count Data. Cambridge, UK: Cambridge University Press.
11. Cameron, A. Colin, and Pravin K. Trivedi. 2005. Microeconometrics Methods and Applications. New York: Cambridge University Press.
12. Chao, Blenda A. 2005. "Evaluating the Educational Content of Direct-to-Consumer Fulfillment Materials." American Journal of Health-System Pharmacy, 62(6): 620-25.
13. Dehez, Pierre, and Alex Jacquemin. 1975. "A Note on Advertising Policy under Uncertainty and Dynamic Conditions." Journal of Industrial Economics, 24(1): 73-78.
14. Donohue, Julie M., Ernst R. Berndt, Meredith Rosenthal, Arnold M. Epstein, and Richard G. Frank. 2004. "Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression." Medical Care, 42(12): 1176-85.
15. Dorfman, Robert, and Peter O. Steiner. 1954. "Optimal Advertising and Optimal Quality." American Economic Review, 44(5): 826-36.
16. Horowitz, Ira. 1970. "A Note on Advertising and Uncertainty." Journal of Industrial Economics, 18(2): 151-60.
17. Iizuka, Toshiaki, and Ginger Zhe Jin. 2005. "The Effect of Prescription Drug Advertising on Doctor Visits." Journal of Economics and Management Strategy, 14(3): 701-27.
18. The Kaiser Family Foundation. 2009. "Trends in Promotional Spending for Prescription Drugs, 1996-2008." http://facts.kff.org/chart.aspx?ch=225.
19. Kravitz, Richard L., Ronald M. Epstein, Mitchell D. Feldman, Carol E. Franz, Rahman Azari, Michael S. Wilkes, Ladson Hinton, and Peter Franks. 2005. "Influence of Patients' Requests for Direct-to- Consumer Advertised Antidepressants: A Randomized Controlled Trial." Journal of the American Medical Association, 293(16): 1995-2002.
20. Lam, Michael D. 2004. "Spend Trends: A $20 Billion Bill and Plenty of Change." Pharmaceutical Executive, September 1. http://pharmexec.findpharma.com/pharmexec/PE+Features/Spend- Trends-A-20-Billion-Bill-and-Plenty-of-Chang/ArticleStandard/Article/detail/123004.
21. Lyles, Alan. 2002. "Direct Marketing of Pharmaceuticals to Consumers." Annual Review of Public Health, 23: 73-91.
22. Masson, A., and P. H. Rubin. 1985. "Matching Prescription Drugs and Consumers--The Benefits of Direct Advertising." New England Journal of Medicine, 313(8): 513-15.
23. Mintzes, Barbara, Morris L. Barer, Richard L. Kravitz, Arminée Kazanjian, Ken Bassett, Joel Lexchin, Robert G. Evans, Richard Pan, and Stephen A. Marion. 2002. "Influence of Direct to Consumer Pharmaceutical Advertising and Patients' Requests on Prescribing Decisions: Two Site Cross Sectional Survey." British Medical Journal, 324(7332): 278-79.
24. Narayanan, Sridhar, Ramarao Desiraju, and Pradeep K. Chintagunta. 2004. "Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions." Journal of Marketing, 68(4): 90-105.
25. Olson, Mary K. 2002. "Pharmaceutical Policy Change and the Safety of New Drugs." Journal of Law and Economics, 45(2): 615-42.
26. Rawson, Nigel S. B., and Kenneth I. Kaitin. 2003. "Canadian and US Drug Approval Times and Safety Considerations." The Annals of Pharmacotherapy, 37(10): 1403-08.
27. Rizzo, John A. 1999. "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs." Journal of Law and Economics, 42(1): 89-116.
28. Rudholm, Niklas. 2004. "Approval Times and the Safety of New Pharmaceuticals." European Journal of Health Economics, 5(4): 345-50.
29. Scherer, F. M. 2000. "The Pharmaceutical Industry." In Handbook of Health Economics, Vol. 1B, ed. Anthony J. Culyer and Joseph P. Newhouse, 1297-1336. New York: North-Holland.
30. Sellers, L. J., and Andra Brichacek. 2001. "Flexing Their Budgets: Big Pharma Spend Trends." Pharmaceutical Executive, September 1. http://pharmexec.findpharma.com/pharmexec/article/article- Detail.jsp?id=780&sk=&date=&pageID=3.
31. Spence, Michele M., Stephanie S. Teleki, T. Craig Cheetham, Stuart O. Schweitzer, and Mirta Millares. 2005. "Direct-to-Consumer Advertising of COX-2 Inhibitors: Effect on Appropriateness of Prescribing." Medical Care Research and Review, 62(5): 544-59.
32. U.S. Food and Drug Administration. 2005. Center for Drug Evaluation and Research 2005 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, MD.
33. U.S. General Accounting Office. 2002. Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations. GAO-03-177. Washington, DC, October.
34. Wazana, Ashley. 2000. "Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?" Journal of the American Medical Association, 283(3): 373-80.
35. West, Diane. 2007. "Spend Trends 2007: Hang 10, DTC Hits Its first Decade." Pharmaceutical Executive, May 1. http://pharmexec.findpharma.com/pharmexec/article/articleDetail.jsp?id=423215&sk=&date=&pageID=3.
36. Windmeijer, Frank, Eric de Laat, Rudy Douven, and Esther Mot. 2006. "Pharmaceutical Promotion and GP Prescription Behaviour." Health Economics, 15(1): 5-18.
37. Wooldridge, Jeffrey M. 2002. Econometric Analysis of Cross Section and Panel Data. Cambridge, MA: MIT Press.